


Financial Overview For Fiscal 2006 Fiscal Year Ended March 31,2006

Yutaka Kobayashi
President and Chief Operating Officer
KOBAYASHI PHARMACEUTICAL CO.,LTD

Consolidated Financial Highlights

	FY2005		FY2006		Change	
	Amount	Profit rate	Amount	Profit rate	Amount	Profit rate
Net Sales	Million Yen	%	Million Yen	%	Million Yen	%
	215,708	_	246,852	-	31,144	14.4
Operating Income	15,698	7.3	16,879	6.8	1,180	7.5
Ordinary Income	14,159	6.6	15,151	6.1	992	7.0
Net Income	6,730	3.1	7,474	3.0	744	11.1
EPS (Yen)	160.64	_	179.17		18.53	11.5


Consolidated Financial Results






Segment Information


Consumer Products Operation



Sales by Category




Contribution Rate of New Products




Sales by Product Brand

Top 10 Product Brand(53% of total sales; 1.2% increase)



Sales by Product Brand

Top 20 Product Brand(70% of total sales;3.2% increase)




Cost Reduction in Manufacturing Divisions


Achieved cost reduction of 1.35 billion yen

Item	Amount		
Improvement in productivity (Improved yield, automation, labor savings)	426million yen		
Price negotiations	371 million yen		
Shift to in-house manufacturing	154million yen		
Use of substitutes and revision of packaging specification	103million yen		
Change of manufacturing sites	54million yen		
Others	246million yen		


Business Results of OverseasSubsidiaries



Wholesale Operation




Medical Devices Operation




Medical Devices Operation

Sales by Category



KMD Sales





Consolidated Financial Forecast FY2007

Group Management Strategy

Promote growth strategy targeting "Sales Growth"

- Achieve plan targets by optimizing individual businesses
- 2. A corporate culture of encouragement and an organization where people learn and grow themselves
- 3. Create a corporate culture that emphasizes execution and where results are fairly evaluated
- 4. Implement reforms and innovations with a thorough emphasis on the frontline
- 5. Give form to "You make a wish and we make it real" brand slogan

Three Growth Strategies

1. New Product Development Involve top management from the early development stage

2.Proactive M&As

Consumer Products Operation
Healthcare-related companies and brands
Wholesale Operation
Advanced into areas not covered
Medical Devices Operation
Strengthen capabilities as a manufacturer

3.Overseas Expansion
Grow business in China, U.K., U.S. and Germany

Growth Strategy for Consumer Products Operation

1.Develop new products

Target:10% of sales from new products

2. Focus on healthcare category

50% of sales from pharmaceutical, oral hygiene products and food

3.M&As

Acquire brands and companies in healthcare domain

4. Target the Chinese market

Concentrate investment in body warmers

System for Developing and Growing Products

Integrated brand development system under category teams

Drugs Product Department			Daily Goods Department			
Pharmac euticals	Oral Care	Foods		Deodorizing air Fresheners	Detergents and Sundries	
		Brand I	lanager			
	Produ	ct Develo	pment Ma	nager		
		R	D			
	Те	hnology	Developm	ent		
		KOBAYASHI PHARMACE	EUTICAL CO.,LTD		19	

New Products in Spring 2006

18 New Products Combined First-Year Sale Target:¥9.3 billion



































Main Areas Targeted in China

- Actively develop body warmer business
- Launch Breath Care in Shanghai region
- Establish research function
- Strengthen sales to leading, large stores (in terms of sales)

Growth Strategy for Wholesale Operation

1.Expand scale and extend geographical coverage

Advance into Tohoku, aim for sales of ¥300 billion

2.Initiate industry realignment

Form alliances with peer companies and companies in different industries

3.Achieve low-cost operations

Integrate systems and logistics for greater efficiency

Growth Strategy for Medical Device Operation



Nurture products commanding top market shares

- 2.Promote in-house product development Develop products to replace and/or improve on existing products
- 3. Rigorously reduce costs

Respond to lowering of official prices

In-house Developed Product KIAPEX KIAPEX Hip Prosthesis System

A femoral head prosthesis for use in treating femoral neck fracture

Targeting annual sales of ¥0.5 billion






movement inside joint

Consolidated Financial Forecasts

	FY2006		FY2007 (Forecast)		Change	
	Amount	Profit rate	Amount	Profit rate	Amount	Profit rate
Net Sales	Million Yen	%	Million Yen	%	Million Yen	%
	246,852	_	268,000	-	21,148	8.6
Operating Income	16,879	6.8	17,800	6.6	921	5.5
Ordinary Income	15,151	6.1	16,000	6.0	849	5.6
Net Income	7,474	3.0	8,600	3.2	1,126	15.1
EPS (Yen)	179.17	_	207.31	_	28.14	15.7

Net Sales and Operating Income



Sale of Shares

Aims: Increase liquidity of company's shares and increase shareholder base

Founding family to sell 3 million shares (approx. 7% of issued shares)

No. of shareholders: 6883

(as of March 31,2006)

⇒ Goal: Increase to 10,000

Dividend Policy and Internal Reserves

Increase returns to shareholders

(Raised dividend ¥5 for March^o 2006 fiscal year)

Secure internal reserves for growth strategy (M&As)

